News | Antiplatelet and Anticoagulation Therapies

Patients who stopped taking aspirin one month after receiving a stent in the heart’s arteries but continued taking the P2Y12 inhibitor clopidogrel fared significantly better after one year compared with those who followed the standard practice of continuing both medications, according to recent research. Stopping aspirin early was found to be superior in terms of the trial’s primary endpoint, a composite of death from cardiovascular causes, heart attack, clotting near the stent, stroke and major bleeding. The data were presented at the American College of Cardiology’s (ACC) 68th Annual Scientific Session, March 16-18 in New Orleans.

Home March 25, 2019
Home
News | Interventional Radiology

NZ Technologies Inc. announced the first published clinical review on its TIPSO technology’s ability to provide wireless, in-suite control of viewing and manipulation of images to physicians. Published in the peer-reviewed journal Vascular Disease Management, the review tested the technology in 15 consecutive cases. The authors found that the TIPSO AirPad improved workflow in a variety of procedures by minimizing the number of episodes of scrubbing out to view images outside the operating room, thereby reducing procedural time.

Home March 25, 2019
Home
News | Pharmaceuticals

Phase 3 results from Study 2, also known as CLEAR WISDOM, of bempedoic acid were recently presented at the American College of Cardiology (ACC) Scientific Sessions & Expo, March 16-18 in New Orleans. Bempedoic acid is being developed as a complementary, cost-effective, convenient, once-daily, oral therapy for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). Bempedoic acid and the bempedoic acid/ezetimibe combination tablet new drug applications have been submitted to the U.S. Food and Drug Administration (FDA), and are under regulatory review for marketing authorization by the European Medicines Agency.

Home March 25, 2019
Home
News | Ventricular Assist Devices (VAD)

Severely ill patients with advanced heart failure who received the HeartMate 3 left ventricular assist device (LVAD) suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with patients who received an older pump. The data came from research presented at the American College of Cardiology’s 68th Annual Scientific Session, March 16-18 in New Orleans.

Home March 22, 2019
Home
Videos | Cardio-oncology

Magid Awadalla, MBBS, is an advanced cardiac imaging research fellow at Massachusetts General Hospital. He has been ...

Home March 22, 2019
Home
News | Heart Valve Technology

Among patients with severe symptomatic aortic stenosis at low surgical risk, transcatheter aortic valve replacement (TAVR) using the Sapien 3 valve compared with conventional surgery significantly reduced the primary endpoint of death, stroke and re-hospitalizations by 46 percent at one year. The data, from the latest PARTNER trial, were presented at the American College of Cardiology’s 68th Annual Scientific Session, March 16-18 in New Orleans. In addition, the rates of death from any cause, stroke and repeat hospitalizations independently favored TAVR at 30 days and at one year, researchers said.

Home March 22, 2019
Home
The most recent U.S. Food and Drug Administration (FDA) clearance was Siemens Healthineers high-sensitivity troponin I assays (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analyzers. The test helps in the early diagnosis of myocardial infarctions without the need for serial tropic testing. The time to first results is 10 minutes.
Feature | Cardiac Diagnostics | Linda C. Rogers, Ph.D.

Troponins are a family of proteins found in skeletal and heart (cardiac) muscle fibers that produce muscular contraction ...

Home March 22, 2019
Home
Concerto CRT-D and Virtuoso ICD implantable cardiac devices are among several Medtronic electrophysiology devices included in a safety alert because of their lack of cybersecurity measures to avoid hacking, according to the FDA.
Feature | EP Lab

March 22, 2019 — The U.S. Food and Drug Administration (FDA) issued a safety communication to alert healthcare providers ...

Home March 22, 2019
Home
Videos | Nuclear Imaging

Raza Alvi, M.D., a research fellow in radiology at Massachusetts General Hospital, has been involved in a study of a ...

Home March 22, 2019
Home
At #ACC.19, Siemens unveiled a version of its go.Top platform optimized for cardiovascular imaging. The newly packaged scanner can generate the data needed to do CT-based FFR (fractional flow reserve).
Feature | Cardiac Imaging | By Greg Freiherr

Reflecting a trend toward the increased use of computed tomography (CT) in cardiology, Siemens Healthineers launched a ...

Home March 22, 2019
Home
Videos | EP Lab

Khaldoun Tarakji, M.D., MPH, associate section head, section of electrophysiology and pacing in the Robert and Suzanne ...

Home March 21, 2019
Home
Videos | Atrial Fibrillation

Christine Albert, M.D., MPH, director of the Center for Arrhythmia Prevention at Brigham and Women’s Hospital, and ...

Home March 21, 2019
Home
News | Cardiovascular Ultrasound

Clinicians should use echocardiography when determining whether patients with heart failure and a leaking heart valve are likely to benefit from valve repair, according to research presented at the American College of Cardiology’s 68th Annual Scientific Session, March 16-18 in New Orleans.

Home March 21, 2019
Home
Technology | Heart Failure

The U.S. Food and Drug Administration (FDA) approved Impulse Dynamics’ Optimizer Smart system for treating patients with chronic, moderate-to-severe heart failure to restore a normal timing pattern of the heartbeat. The device is indicated for patients who are not suited for treatment with other heart failure devices such as cardiac resynchronization therapy. The FDA gave the Optimizer Smart system a Breakthrough Device designation because it treats a life-threatening disease, heart failure, and addresses an unmet medical need in patients who fail to get adequate benefits from standard treatments and have no alternative treatment options.

Home March 21, 2019
Home
News | EP Lab

Results from the landmark Worldwide Randomized Antibiotic Envelope Infection Prevention Trial (WRAP-IT) demonstrated Medtronic’s Tyrx Absorbable Antibacterial Envelope reduced the risk of major infection by 40 percent, and pocket infection by 61 percent, in patients with cardiac implantable electronic devices (CIEDs). The improvements were in comparison to standard-of-care pre-operative antibiotics. The trial results were presented in a late-breaking session at the American College of Cardiology’s 68th Annual Scientific Sessions (ACC.19), March 16-18 in New Orleans, and published simultaneously in The New England Journal of Medicine.

Home March 20, 2019
Home
Subscribe Now